Wael A Alghamdi (W A Alghamdi)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 15

Top Venues

Antimicrobial agents and chemotherapy

Healthcare (Basel, Switzerland)

Journal of clinical medicine

Expert review of clinical pharmacology

King Khalid University

University of Florida (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

King Khalid University

Saudi Arabia

Assistant Professor :: Clinical Pharmacy

University of Florida

United States

Teaching Assistant :: Department of Pharmacotherapy and Translational Research

King Khalid University

Saudi Arabia

Teaching Assistant :: Clinical Pharmacy

Education History

University of Florida

United States

PHD :: Pharmacotherapy and Translational Research

Massachusetts College of Pharmacy and Health Sciences

United States

PHD :: Pharmacy

King Khalid University

Saudi Arabia

BSC :: Pharmacy

Publications

Tahani Musleh Almeleebia, Khalid M Orayj, Wael A Alghamdi, Mona A Almanasef, Omar Hany, Ahmed R N Ibrahim
Evaluation of Pharmacy Intern Interventions on Antimicrobial Use in University-Affiliated Hospitals: A Retrospective Analysis. Journal of clinical medicine 13 (17) (2024)
Daniel S Graciaa, Maia Kipiani, Matthew J Magee, Lali Mikiashvili, Ketevan Barbakadze, Nino Bablishvili, Sara C Auld, Wael A Alghamdi, Mohammad H Alshaer, Charles A Peloquin, Zaza Avaliani, Henry M Blumberg, Russell R Kempker
Linezolid Exposure Is Associated with Cytopenias in Patients Treated for Multidrug-Resistant Tuberculosis. Antimicrobial agents and chemotherapy 66 (9) (2022)
Wael A Alghamdi, Tahani Musleh Almeleebia, Khalid M Orayj
Comparison of Saudi Pharmacist Licensure Examination (SPLE) Pass Rates by Institution and Applicant Characteristics. Healthcare (Basel, Switzerland) 10 (10) (2022)
Abdullah Alsultan, Mohammad H Alshaer, Wael A Alghamdi, Charles A Peloquin
Comment on: The case for 'conservative pharmacotherapy'. The Journal of antimicrobial chemotherapy 76 (7) (2021)
Mohammad H Alshaer, Anne-Grete Märtson, Wael A Alghamdi, Abdullah Alsultan, Guohua An, Shahriar Ahmed, Yosra Alkabab, Sayera Banu, Eric R Houpt, David Ashkin, David E Griffith, J Peter Cegielski, Scott K Heysell, Charles A Peloquin
Ethionamide Population Pharmacokinetic Model and Target Attainment in Multidrug-Resistant Tuberculosis. Antimicrobial agents and chemotherapy 64 (9) (2020)
Wael A Alghamdi, Mohammad H Alshaer, Kenneth P Klinker, Charles A Peloquin
Variable linezolid exposure and response and the role of therapeutic drug monitoring: Case series. Clinical case reports 8 (7) (2020)
Wael A Alghamdi, Mohammad H Alshaer, Guohua An, Abdullah Alsultan, Maia Kipiani, Ketevan Barbakadze, Lali Mikiashvili, David Ashkin, David E Griffith, J Peter Cegielski, Russell R Kempker, Charles A Peloquin
Population Pharmacokinetics of Linezolid in Tuberculosis Patients: Dosing Regimen Simulation and Target Attainment Analysis. Antimicrobial agents and chemotherapy 64 (10) (2020)
Wael A Alghamdi, Abdullah Alsultan, Mohammad H Alshaer, Guohua An, Shahriar Ahmed, Yosra Alkabab, Sayera Banu, Ketevan Barbakadze, Eric Houpt, Maia Kipiani, Lali Mikiashvili, Stephan Schmidt, Scott K Heysell, Russell R Kempker, J Peter Cegielski, Charles A Peloquin
Cycloserine Population Pharmacokinetics and Pharmacodynamics in Patients with Tuberculosis. Antimicrobial agents and chemotherapy 63 (5) (2019)
Mohammad H Alshaer, Wael A Alghamdi, Abdullah Alsultan, Guohua An, Shahriar Ahmed, Yosra Alkabab, Sayera Banu, Ketevan Barbakadze, Eric Houpt, Maia Kipiani, Lali Mikiashvili, J Peter Cegielski, Russell R Kempker, Scott K Heysell, Charles A Peloquin
Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection. Antimicrobial agents and chemotherapy 63 (7) (2019)
Russell R Kempker, Wael A Alghamdi, Mohammad H Alshaer, Gena Burch, Charles A Peloquin
A Pharmacology Perspective of Simultaneous Tuberculosis and Hepatitis C Treatment. Antimicrobial agents and chemotherapy (2019)
Anthony Enimil, Sampson Antwi, Hongmei Yang, Albert Dompreh, Wael A Alghamdi, Fizza S Gillani, Antoinette Orstin, Dennis Bosomtwe, Theresa Opoku, Jennifer Norman, Lubbe Wiesner, Taimour Langaee, Charles A Peloquin, Michael H Court, David J Greenblatt, Awewura Kwara
Effect of First-Line Antituberculosis Therapy on Nevirapine Pharmacokinetics in Children Younger than Three Years Old. Antimicrobial agents and chemotherapy 63 (10) (2019)
Awewura Kwara, Hongmei Yang, Sampson Antwi, Anthony Enimil, Fizza S Gillani, Albert Dompreh, Antoinette Ortsin, Theresa Opoku, Dennis Bosomtwe, Anima Sarfo, Lubbe Wiesner, Jennifer Norman, Wael A Alghamdi, Taimour Langaee, Charles A Peloquin, Michael H Court, David J Greenblatt
Effect of Rifampin-Isoniazid-Containing Antituberculosis Therapy on Efavirenz Pharmacokinetics in HIV-Infected Children 3 to 14 Years Old. Antimicrobial agents and chemotherapy 63 (1) (2018)
Wael A Alghamdi, Mohammad H Alshaer, Charles A Peloquin
Protein Binding of First-Line Antituberculosis Drugs. Antimicrobial agents and chemotherapy 62 (7) (2018)
Christoph Lange, Wael A Alghamdi, Mohammad H Alshaer, Susanna Brighenti, A H Diacon, A R DiNardo, H P Grobbel, M I Gröschel, F von Groote-Bidlingmaier, M Hauptmann, J Heyckendorf, N Köhler, T A Kohl, M Merker, S Niemann, C A Peloquin, M Reimann, U E Schaible, D Schaub, V Schleusener, T Thye, T Schön
Perspectives for personalized therapy for patients with multidrug-resistant tuberculosis. Journal of internal medicine (2018)
Omamah Alfarisi, Wael A Alghamdi, Mohammad H Alshaer, Kelly E Dooley, Charles A Peloquin
Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis? Expert review of clinical pharmacology 10 (10) (2017)

Wael A Alghamdi.css-eqlu8i{font-size:small;padding-left:4px;} (W A Alghamdi)

Publication Activity (10 Years)

Top Topics

Top Venues

Wael A Alghamdi (W A Alghamdi)